Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study
Daniel K. Nomah(Universitat Autònoma de Barcelona), Bibiana Morell, Adrián Curran(Lexington City Schools), Lucía Rodríguez‐Vázquez, Sergio Moreno‐Fornés(Generalitat de Catalunya), Javier Murillas, José Vicente Fernández-Montero, Francesc Vidal(Institut de Recerca Biomèdica Catalunya Sud), Josep M. Llibre(Badalona Serveis Assistencials), Toni Vanrell, Hernando Knobel(Hospital General de Granollers), Àngels Masabeu(Hospital de Palamós), Anna Esteve(Harvard University), Jose Carlos Rubia, Joaquín Burgos, Elisabet Deig, Amat-Joaquim Orti, Arkaitz Imaz(Bellvitge University Hospital), Emili Letang(Hospital Del Mar), Ángeles Jaén, Josep Mallolas(Hospital Clínic de Barcelona), Lluís Force(University Hospital Mútua de Terrassa), Josep Vilà(Hospital Universitari de Vic), Marina Martínez, Vicenç Falcó(Universitat Autònoma de Barcelona), Rosa Maria Vivanco‐Hidalgo(Agència de Qualitat i Avaluació Sanitàries de Catalunya), Jordi Aceitón(Generalitat de Catalunya), Eva López González, Leire Berrocal, Peré Domingo(Hospital de Sant Pau), Francisco Homar, Juliana Reyes‐Urueña(Generalitat de Catalunya), Yesika Díaz(Institut Universitari d'Investigació en Atenció Primària Jordi Gol), Freya Gargoulas, Andreu Bruguera(Badalona Serveis Assistencials), José M Miró(Instituto de Salud Carlos III), David Dalmau(University Hospital Mútua de Terrassa), Gemma Navarro(Corporació Sanitària Parc Taulí), Elisa de Lazzari(Hospital Clínic de Barcelona), Guillem Fernandez, Daniel Podzamczer(Bellvitge University Hospital), Jordi Casabona(Generalitat de Catalunya), Joaquim Peraire(Instituto de Salud Carlos III), María del Mar Gutiérrez(Evidence (Italy)), Elena León, Melchor Riera(Instituto de Salud Carlos III), María Gracia Mateo, Cristina Cortés(Hospital de Sant Joan Despí Moisès Broggi), Ingrid Vilaró(Hospital Universitari de Vic), Esteve Muntada
Cited by 110
Related Papers
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
|Science Immunology|2021|638
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)
|Open Forum Infectious Diseases|2020|215
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
|Proceedings of the National Academy of Sciences|2022|198
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143